Paper40927152
Improving Brain Tumor Treatment through Nanotechnology and Proton Therapy Using Laser-driven Accelerators through GEANT4 Simulation.
Kavehnia M and 2 others. Indian J Nucl Med, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Improving Brain Tumor Treatment through Nanotechnology and Proton Therapy Using Laser-driven Accelerators through GEANT4 Simulation. Papers, record 40927152. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40927152
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Improving Brain Tumor Treatment through Nanotechnology and Proton Therapy Using Laser-driven Accelerators through GEANT4 Simulation.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39025943 | Radiotherapy-triggered reduction of platinum-based chemotherapeutic prodrugs in tumours. | Nat Biomed Eng | 2024 | https://conductscience.org/library/papers/39025943 | PubMed |
| 2 | 28976361 | RBE and related modeling in carbon-ion therapy. | Phys Med Biol | 2017 | https://conductscience.org/library/papers/28976361 | PubMed |
| 3 | 37174022 | Image-Guided Proton Therapy: A Comprehensive Review. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37174022 | PubMed |
| 4 | 26155318 | Nanoparticles for Radiation Therapy Enhancement: the Key Parameters. | Theranostics | 2015 | https://conductscience.org/library/papers/26155318 | PubMed |
| 5 | 36902132 | Mechanisms of Nanoscale Radiation Enhancement by Metal Nanoparticles: Role of Low Energy Electrons. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36902132 | PubMed |
| 6 | 2946403 | A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. | Cancer Res | 1986 | https://conductscience.org/library/papers/2946403 | PubMed |
| 7 | 25953956 | Biological modeling of gold nanoparticle enhanced radiotherapy for proton therapy. | Phys Med Biol | 2015 | https://conductscience.org/library/papers/25953956 | PubMed |
| 8 | 28150217 | Nanoparticle-Mediated X-Ray Radiation Enhancement for Cancer Therapy. | Methods Mol Biol | 2017 | https://conductscience.org/library/papers/28150217 | PubMed |
| 9 | 18644191 | Radiotherapy enhancement with gold nanoparticles. | J Pharm Pharmacol | 2008 | https://conductscience.org/library/papers/18644191 | PubMed |
| 10 | 36873996 | Nanoparticle-based radiosensitization strategies for improving radiation therapy. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/36873996 | PubMed |
| 11 | 27399787 | Protection against Radiotherapy-Induced Toxicity. | Antioxidants (Basel) | 2016 | https://conductscience.org/library/papers/27399787 | PubMed |
| 12 | 21915155 | Enhanced relative biological effectiveness of proton radiotherapy in tumor cells with internalized gold nanoparticles. | Appl Phys Lett | 2011 | https://conductscience.org/library/papers/21915155 | PubMed |
| 13 | 29125831 | Nanoparticle radio-enhancement: principles, progress and application to cancer treatment. | Phys Med Biol | 2018 | https://conductscience.org/library/papers/29125831 | PubMed |
| 14 | 23201628 | Enhanced proton treatment in mouse tumors through proton irradiated nanoradiator effects on metallic nanoparticles. | Phys Med Biol | 2012 | https://conductscience.org/library/papers/23201628 | PubMed |
| 15 | 31725910 | Gold nanoparticle enhanced proton therapy: A Monte Carlo simulation of the effects of proton energy, nanoparticle size, coating material, and coating thickness on dose and radiolysis yield. | Med Phys | 2020 | https://conductscience.org/library/papers/31725910 | PubMed |
| 16 | 35110613 | Comparing Geant4 physics models for proton-induced dose deposition and radiolysis enhancement from a gold nanoparticle. | Sci Rep | 2022 | https://conductscience.org/library/papers/35110613 | PubMed |
| 17 | 36160180 | A Review of Proton Therapy - Current Status and Future Directions. | Precis Radiat Oncol | 2022 | https://conductscience.org/library/papers/36160180 | PubMed |
| 18 | 37704633 | Facile preparation of silver based radiosensitizers via biomineralization method for enhanced in vivo breast cancer radiotherapy. | Sci Rep | 2023 | https://conductscience.org/library/papers/37704633 | PubMed |
| 19 | 25415297 | Comparing gold nano-particle enhanced radiotherapy with protons, megavoltage photons and kilovoltage photons: a Monte Carlo simulation. | Phys Med Biol | 2014 | https://conductscience.org/library/papers/25415297 | PubMed |
| 20 | 25361443 | Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer. | Phys Med Biol | 2014 | https://conductscience.org/library/papers/25361443 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40927152
GET https://conductscience.org/api/papers/v1/40927152/references?page=2